Core Insights - RTW Investments initiated a new stake in Apellis Pharmaceuticals by acquiring 7,666,764 shares in the fourth quarter of 2025, valued at $192.59 million as of the quarter-end [2][6]. Company Overview - Apellis Pharmaceuticals is a commercial-stage biotechnology company focused on innovative therapies for complement-driven diseases, with a robust pipeline and growing commercial portfolio [5]. - The company generated approximately $689 million in product revenue last year, primarily from its flagship therapy, which accounted for about $587 million, and an additional $102 million from its second product [7][8]. - As of the latest data, Apellis has a revenue of $1 billion and a net income of $22.4 million, with a market capitalization of $2.2 billion [4]. Investment Implications - The investment by RTW Investments represents a calculated pivot towards more durable revenue streams, as Apellis accounts for 1.93% of the fund's 13F reportable assets under management (AUM) as of December 31, 2025 [7][10]. - Despite a 29% decline in Apellis shares over the past year, the company shows signs of real demand and expanding market share in the rare disease markets, which may attract disciplined biotech investors [6][9].